Related Experiment Videos
Development of a potent thrombin receptor ligand
D M Feng1, D F Veber, T M Connolly
1Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
Journal of Medicinal Chemistry
|September 29, 1995
Summary
Researchers designed a potent thrombin receptor agonist peptide, significantly enhancing its activation capabilities. This breakthrough offers a highly effective tool for studying thrombin receptor function and potential therapeutic applications.
Area of Science:
- Biochemistry
- Pharmacology
Background:
- The N-terminal thrombin receptor peptide (1) activates the thrombin receptor with an EC50 of 10 microM.
- Structural features of the tetradecapeptide responsible for receptor activation were investigated.
Purpose of the Study:
- To elucidate structural features responsible for thrombin receptor activation.
- To design and synthesize more potent thrombin receptor agonists.
- To develop a radioligand for thrombin receptor studies.
Main Methods:
- Peptide synthesis and structural modification.
- Receptor activation assays to determine EC50 values.
- Design of shortened and modified peptide analogs.
Main Results:
- The initial peptide (1) showed full thrombin receptor activation at 10 microM.
- A novel shortened peptide analog (56) demonstrated a 1000-fold increase in potency, with an EC50 of 0.01 microM.
- A monoiodinated derivative (59) exhibited an EC50 of 0.03 microM, suitable for radioligand development.
Conclusions:
- Structural modifications can significantly enhance thrombin receptor agonist potency.
- Peptide analog 56 represents the most potent agonist reported to date.
- Peptide analog 59 is a promising candidate for developing a radioligand for thrombin receptor research.